SCHEMBL20119574

SCHEMBL20119574

Cc1cccc(CCNc2ncnc3[nH]cnc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
HTT P42858 3/20 0.47
TAAR1 Q96RJ0 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 2/20 0.46
KCNK2 O95069 1/20 0.45
TP53 P04637 1/20 0.43
TSHR P16473 3/20 0.43
HSD17B10 Q99714 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
BTK Q06187 1/20 0.42
LMNA P02545 2/20 0.42
GALR3 O60755 1/20 0.41
SLC29A1 Q99808 1/20 0.41
ALOX15 P16050 2/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30850682 0.87 CYP1A2 (0.60) MAPK1CYP1A2TP53TSHRHSD17B10
SCHEMBL4921700 0.87 CYP1A2 (0.60) MAPK1CYP1A2TP53TSHRHSD17B10
SCHEMBL20119671 0.85 AURKA (0.52) HTTTAAR1MAPK1TP53TSHR
SCHEMBL20119570 0.84 TP53 (0.62) POLBHTTTAAR1MAPK1CYP1A2
SCHEMBL20119324 0.84 GALR3 (0.58) HTTTAAR1MAPK1TP53TSHR
SCHEMBL9609211 0.84 MAPK1 (0.64) HTTTAAR1MAPK1CYP1A2TSHR
SCHEMBL20119580 0.82 AURKA (0.45) HTTTAAR1MAPK1MAPTNPSR1
SCHEMBL20119357 0.79 HTT (0.48) HTTTAAR1MAPK1CYP1A2TSHR
SCHEMBL30850528 0.79 HTT (0.48) HTTTAAR1MAPK1CYP1A2TSHR
SCHEMBL20119632 0.78 HTT (0.49) HTTTAAR1MAPK1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885HTT 326/4885TAAR1 4258/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885HTT 326/4885TAAR1 4258/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885HTT 326/4885TAAR1 4258/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885HTT 326/4885TAAR1 4258/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 POLB 989/4885HTT 326/4885TAAR1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.